One such early stage opportunity is a topical treatment to reduce cellulite. CRF100 - Celluilite Reduction Formula - is a topically applied cream comprising a well-characterised alkaloid with Futura’s highly efficient DermaSys® delivery system. The alkaloid is already used by a number of major cosmetics companies in the treatment of cellulite and its use, at levels sufficient to produce a physiological effect, is supported by a growing body of scientific literature.
In in vitro trials, CRF100 has been shown to achieve at least an eight-fold improvement in delivery of the alkaloid through the skin compared with a number of market leading comparator products. The Company believes that this enhanced permeation, delivered by the DermaSys® system, will result in a physiologically active dose of the alkaloid in the subcutaneous tissues, the target site for the treatment of cellulite.
It is intended that CRF100 will be an over-the-counter product and will be licensed at an appropriate time to a major global company for commercialisation. A number of patent applications covering DermaSys® are in various stages of grant or prosecution and further applications may be considered pending the achievement of successful clinical outcomes.
Although classified as a cosmoceutical, the Company will develop CRF100 in line with the robust scientific principles and evidence-based approach used throughout its portfolio of products. A pivotal study is expected to take place during 2012 within Europe.
We are evaluating further product opportunities for our proprietary delivery system DermaSys® with a range of other compounds.